Приклади вживання Linezolid Англійська мовою та їх переклад на Українською
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Similarly, linezolid does not induce P450 isoenzymes in rats.
In the treatment of Staphylococcus aureus in the intestine are frequently used antibiotics: vancomycin, Kubica,Ceftobiprole, linezolid.
Similarly, linezolid does not induce P450 isoenzymes in rats.
No resistance of none of these pathogens to amikacin, tobramycin, netilmicin, linezolid, vancomycin and teicoplanin was observed.
Linezolid is also highly active in vitro against several mycobacteria.
When given for short periods, linezolid is a relatively safe antibiotic.
Linezolid appears to be as safe and effective for use in children and newborns as it is in adults.
Active substance therein protrudes linezolid, belonging to the group of oxazolidinone.
Linezolid is readily distributed to all tissues in the body apart from bone matrix and white adipose tissue.
Drugs such as warfarin and phenytoin, which are CYP2C9 substrates,may be given with linezolid without changes in dosage regimen.
Resistance to linezolid is associated with point mutations in the 23S rRNA.
There are insufficientdata from patients who have received warfarin and linezolid to assess the clinical significance, if any, of these findings.
Linezolid primarily contains(s)-linezolid which is biologically active and is metabolised to form inactive derivatives.
First discovered during the 1990's and approved for the market in 2000, linezolid was the first commercially available oxazolidinone antibiotic.
Therefore, linezolid is not expected to affect the pharmacokinetics of other drugs metabolized by these major enzymes.
Due to this unique mechanism of action, cross-resistance between linezolid and other protein synthesis inhibitors is highly infrequent or nonexistent.
Linezolid decreased fertility and reproductive performance of male rats at exposure levels approximately equal to those expected in humans.
In compassionate use studies, a higher incidence of seriousanaemia was reported in patients receiving linezolid for more than the maximum recommended duration of 28 days.
In adolescents(12 to 17 years old), linezolid pharmacokinetics were similar to that in adults following a 600mg dose.
Patient should be monitored for symptoms of serotonin syndrome for 2 weeks oruntil 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first.
In controlled clinical trials where linezolid was administered for up to 28 days, less than 0.1% of the patients reported anaemia.
The patient should be monitored for symptoms of serotonin syndrome for 7days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first.
They have new TB drugs, such as linezolid, delamanid, and bedaquiline, as the main drugs of choice for the drug-resistant TB treatment.
Linezolid binds to the 23S portion of the 50S subunit(the center of peptidyl transferase activity), close to the binding sites of chloramphenicol, lincomycin, and other antibiotics.
In both the popular press and the scientific literature, linezolid has been called a"reserve antibiotic"- one that should be used sparingly so that it will remain effective as a drug of last resort against potentially intractable infections.
Linezolid concentrations have been determined in various fluids from a limited number of subjects in Phase 1 volunteer studies following multiple dosing of linezolid.
If you take drugs that have been introduced since then- linezolid or daptomycin- those are significantly more expensive, so to a world that has been used to paying 10 cents a day for antibiotics, the idea of paying 180 dollars per day seems like a lot.
Linezolid is quite expensive; a course of treatment may cost one or two thousand U.S. dollars for the drug alone,[5] not to mention other costs(such as those associated with hospital stay).
Like nearly all antibiotics, linezolid has been associated with Clostridium difficile-associated diarrhea(CDAD) and pseudomembranous colitis, although the latter is uncommon, occurring in about one in two thousand patients in clinical trials.